Global Information Inc. would like to present a new market research report, "The New Generation of Antibody Therapeutics: Current Status and Future Prospects" by Insight Pharma Reports.
With antibody sales projected to reach $50 billion this year, predictions for the future of cutting-edge antibody technologies are that robust growth will continue despite the many roadblocks and uncertainties in the overall picture of drug development. While the market will continue to be dominated by whole antibody molecules, it is anticipated that bispecific antibodies and antibody-drug conjugates will be a growing component of the overall market.
The commercial clinical pipeline for antibodies is growing at a rate of 50 55 new mAbs per year. Today, about 314 mAb products are in clinical trials worldwide. The New Generation of Antibody Therapeutics: Current Status and Future Prospects reviews antibodies in clinical development, profiles selected companies that may contribute to the next generation of cutting-edge antibody technology, and discusses notable collaborations within the antibody industry.
This Insight Pharma report focuses on recent developments in the therapeutic antibody field and new technologies built on the foundations of previously successful and unsuccessful strategies. The new report discusses recent developments in bioprocessing relevant to the needs of the antibody sector. Also discussed are biosimilar antibody drugs, which are the subject of much interest with many patent expirations taking place. While the FDA has yet to approve a biosimilar, many large companies have been moving forward aggressively on such products. Insight Pharma reviews challenges and opportunities, commercial development and the marketplace, as well as regulatory issues concerning biosimilars.
Global Information Inc.(GII) - specializing in market research provision for the vertical industries, GII offers expert independent recommendations of publications from hundreds of the globe's leading market research firms.